Genome sequencing reveals novel deletions associated with secondary resistance to pyrazinamide in MDR Mycobacterium tuberculosis

Journal of Antimicrobial Chemotherapy

Volumn 70, Issue 9, 2015, Pages 2511-2514

  Martinez, Elena ^a,b,c,d   Holmes, Nadine ^b,c,d   Jelfs, Peter ^c,d   Sintchenko, Vitali ^b,c,d  

^a CENTENARY INSTITUTE   (Australia)

^b University of Sydney   (Australia)

^c Institute of Clinical Pathology and Medical Research NSW Health Pathology   (Australia)

^d WESTMEAD HOSPITAL   (Australia)

Author keywords

Multidrug resistant tuberculosis; Pyrazinamide resistance; Whole genome sequencing

Indexed keywords

AMIKACIN; AMINOSALICYLIC ACID; CAPREOMYCIN; CONTIG; CYCLOSERINE; ETHAMBUTOL; ISONIAZID; KANAMYCIN; MOLECULAR MARKER; MOXIFLOXACIN; OFLOXACIN; PROTIONAMIDE; PYRAZINAMIDE; RIFAMPICIN; BACTERIAL DNA; TUBERCULOSTATIC AGENT;

AMPLICON; ANTIBIOTIC RESISTANCE; ARTICLE; AUSTRALIA; BACTERIAL GENE; BACTERIAL GENOME; BACTERIAL STRAIN; BACTERIUM ISOLATE; COMPARATIVE STUDY; CONTROLLED STUDY; DFRA GENE; GENE DELETION; GENE SEQUENCE; HUMAN; LUNG TUBERCULOSIS; MULTIDRUG RESISTANT TUBERCULOSIS; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PNCA GENE; POLYMERASE CHAIN REACTION; RECURRENT DISEASE; RELAPSE; THYA GENE; WHOLE GENOME SEQUENCING; CHEMISTRY; DNA MUTATIONAL ANALYSIS; DNA SEQUENCE; DRUG EFFECTS; GENETICS; MOLECULAR GENETICS; MULTIDRUG RESISTANCE; NEW SOUTH WALES;

ANTITUBERCULAR AGENTS; DNA MUTATIONAL ANALYSIS; DNA, BACTERIAL; DRUG RESISTANCE, MULTIPLE, BACTERIAL; GENES, BACTERIAL; GENOME, BACTERIAL; HUMANS; MOLECULAR SEQUENCE DATA; MYCOBACTERIUM TUBERCULOSIS; NEW SOUTH WALES; POLYMERASE CHAIN REACTION; PYRAZINAMIDE; SEQUENCE ANALYSIS, DNA; SEQUENCE DELETION;

EID: 84954207692     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkv128     Document Type: Article

References (20)

1. WHO. Global Tuberculosis Report 2013. Geneva: WHO, 2013. http://apps.who.int/iris/bitstream/10665/91355/1/9789241564656_eng.pdf.
2. Mphahlele M, Syre H, Valvatne H et al. Pyrazinamide resistance among South African multidrug-resistant Mycobacterium tuberculosis isolates. J Clin Microbiol 2008; 46: 3459-64.
3. Aono A, Chikamatsu K, Yamada H et al. The association between pncA gene mutations, pyrazinamidase activity, and pyrazinamide susceptibility testing in Mycobacterium tuberculosis. Antimicrob Agents Chemother 2014; 58: 4928-30.
4. Juréen P, Werngren J, Toro J-C et al. Pyrazinamide resistance and pncA gene mutations in Mycobacterium tuberculosis. Antimicrob Agents Chemother 2008; 52: 1852-4.
5. Dormandy J, Somoskovi A, Kreiswirth BN et al. Discrepant results between pyrazinamide susceptibility testing by the reference BACTEC 460TB method and pncA DNA sequencing in patients infected with multidrug-resistant W-Beijing Mycobacterium tuberculosis strains. Chest 2007; 131: 497-501.
6. Simons SO, Mulder A, van Ingen J et al. Role of rpsA gene sequencing in diagnosis of pyrazinamide resistance. J Clin Microbiol 2013; 51: 382.
7. Merker M, Kohl TA, Roetzer A et al. Whole genome sequencing reveals complex evolution patterns of multidrug-resistant Mycobacterium tuberculosis Beijing strains in patients. PLoS One 2013; 8: e82551.
8. Scorpio A, Lindholm-Levy P, Heifets L et al. Characterization of pncAmutations in pyrazinamide-resistant Mycobacterium tuberculosis. Antimicrob Agents Chemother 1997; 41: 540-3.
9. Campbell PJ, Morlock GP, Sikes RD et al. Molecular detection of mutations associated with first-and second-line drug resistance compared with conventional drug susceptibility testing of Mycobacterium tuberculosis. Antimicrob Agents Chemother 2011; 55: 2032-41.
10. Supply P, Lesjean S, Savine E et al. Automated high-throughput genotyping for study of global epidemiology of Mycobacterium tuberculosis based on mycobacterial interspersed repetitive units. J ClinMicrobiol 2001; 39: 3563-71.
11. Wang CC, Zhu B, Fan X et al. Systems approach to tuberculosis vaccine development. Respirology 2013; 18: 412-20.
12. Fivian-Hughes AS, Houghton J, Davis EO. Mycobacterium tuberculosis thymidylate synthase gene thyX is essential and potentially bifunctional, while thyA deletion confers resistance to p-aminosalicylic acid. Microbiology 2012; 158: 308-18.
13. Wengenack NL, Lane BD, Hill PJ et al. Purification and characterization of Mycobacterium tuberculosis KatG, KatG(S315T), and Mycobacterium bovis KatG(R463L). Protein Expr Purif 2004; 36: 232-43.
14. Darling ACE, Mau B, Blattner FR et al. Mauve: multiple alignment of conserved genomic sequence with rearrangements. Genome Res 2004; 14: 1394-403.
15. Zhao L-L, Chen Y, Chen Z-N et al. Prevalence and molecular characteristics of drug-resistant Mycobacterium tuberculosis in Hunan, China. Antimicrob Agents Chemother 2014; 58: 3475-80.
16. Kurbatova EV, Cavanaugh JS, Dalton T et al. Epidemiology of pyrazinamide-resistant tuberculosis in the United States, 1999-2009. Clin Infect Dis 2013; 57: 1081-93.
17. Köser CU, Bryant JM, Becq J et al. Whole-genome sequencing for rapid susceptibility testing of M. tuberculosis. N Engl J Med 2013; 369: 290-2.
18. Outhred AC, Jelfs P, Suliman B et al. Added value of whole-genome sequencing for management of highly drug-resistant TB. J Antimicrob Chemother 2015; 70: 1198-202.
19. Miotto P, Cabibbe AM, Feuerriegel S et al. Mycobacterium tuberculosis pyrazinamide resistance determinants: a multicenter study. mBio 2014; 5: e01819-14.
20. Köser C, Comas I, Feuerriegel S et al. Genetic diversity within Mycobacterium tuberculosis complex impacts on the accuracy of genotypic pyrazinamide drug-susceptibility assay. Tuberculosis 2014; 94: 451-3.